TherapeuticsMD proposes $40 million follow-on

Women's health company TherapeuticsMD Inc. (NYSE-M:TXMD) proposed late Tuesday to raise $40 million in a follow-on underwritten by Goldman Sachs and Noble Capital Markets. TherapeuticsMD is developing a pipeline of hormone therapy products for menopause-related hormone deficiencies, with two products in Phase III testing: TX 12-001HR, an oral combination of estradiol and progesterone; and TX 12-002HR, an oral progesterone. The company also markets branded and generic prescription prenatal vitamins, as well as OTC vitamins and cosmetics. ...